Clinical prospects of WRN inhibition as a treatment for MSI tumours

• 发表在: npj Precision Oncology
• Main Authors: David A. Morales-Juarez, Stephen P. Jackson
• 格式: 文件
• 语言: 英语
• 出版: Nature Portfolio 2022-11-01
• 在线阅读: https://doi.org/10.1038/s41698-022-00319-y

Abstract The discovery of synthetic lethal interactions with genetic deficiencies in cancers has highlighted several candidate targets for drug development, with variable clinical success. Recent work has unveiled a promising synthetic lethal interaction between inactivation/inhibition of the WRN DNA helicase and tumours with microsatellite instability, a phenotype that arises from DNA mismatch repair deficiency. While these and further studies have highlighted the therapeutic potential of WRN inhibitors, compounds with properties suitable for clinical exploitation remain to be described. Furthermore, the complexities of MSI development and its relationship to cancer evolution pose challenges for clinical prospects. Here, we discuss possible paths of MSI tumour development, the viability of WRN inhibition as a strategy in different scenarios, and the necessary conditions to create a roadmap towards successful implementation of WRN inhibitors in the clinic.